-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QNGPYkUnaOLtC6fu0gV0a3ErUzUpe0XR1O85SsqgFejraBcNv4FzQwKya2KWSdO9
 RBcWX7dBH84OWfrVurMZ7g==

<SEC-DOCUMENT>0001102624-07-000199.txt : 20070803
<SEC-HEADER>0001102624-07-000199.hdr.sgml : 20070803
<ACCEPTANCE-DATETIME>20070803162555
ACCESSION NUMBER:		0001102624-07-000199
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070803
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070803
DATE AS OF CHANGE:		20070803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		071024372

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucellcorporation8k.htm
<DESCRIPTION>IMMUCELL CORPORATION 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: August    03, 2007</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive, Portland, Maine</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>(207) 878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On August 3, 2007 ImmuCell Corporation (the "Company") issued a press release announcing its financial results for the three and six month periods ended June 30, 2007.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.  The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act ("the Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br>
<br><b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Shell company transactions:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated August    03, 2007</a></b>
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table>
<tr>
<td width="50%" valign=top>
Dated: August    03, 2007<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated August    03, 2007</td>
</tr>
</table>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL CORPORATION PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for Second Quarter Of 2007</b>
<p>PORTLAND, ME -- 08/03/2007 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three and six month periods
ended June 30, 2007.
</p>
<p>
For the three months ended June 30, 2007, product sales were $791,000,
representing an increase of $41,000, or 6%, in comparison to the same
period in 2006. The Company incurred a net loss of $60,000 ($0.02 per
diluted share) during the three months ended June 30, 2007, in contrast to
net income of $16,000 ($0.01 per diluted share) during the same period in
2006.
</p>
<p>
For the six months ended June 30, 2007, product sales were $2,300,000,
representing an increase of $113,000, or 5%, in comparison to the same
period in 2006.  The Company recognized net income of $237,000 ($0.08 per
diluted share) during the six months ended June 30, 2007, compared to net
income of $322,000 ($0.11 per diluted share) during the same period in
2006.
</p>
<p>
"While more would always be better, 5% sales growth is reasonable for our
current products in our current markets," said Michael F. Brigham,
President and CEO, commenting on the product sales increase during the six
month period ended June 30, 2007 in comparison to the same period in 2006.
"The small loss in the second quarter was largely caused by a lower than
expected gross margin on product sales and increased product development
expenses."
</p>
<p>
On July 19, 2007, ImmuCell announced that Pfizer Animal Health had elected
to terminate its product development and marketing agreement covering Mast
Out&#174; and return the product rights to ImmuCell.  As a result of this
termination, the Company expects to recognize the remaining deferred income
from non-refundable milestone payments received from Pfizer and to
write-off the remaining unamortized cost of associated technology license
rights.  This will result in a net increase to income before income taxes
of approximately $602,000 during the third quarter of 2007, with no impact
on cash.
</p>
<p>
"Because we believe that the termination decision was primarily market
driven, rather than arising from any unanticipated efficacy or regulatory
issues, we intend to carry on the product development efforts for Mast
Out&#174;," said Michael F. Brigham, President and CEO.  "Having access to the
new space provided by the recently completed renovation of our facility is
very timely and better positions us to develop the product."
</p>
<p>
Cash, cash equivalents and short-term investments decreased by 16%, or
$1,090,000, to $5,524,000 at June 30, 2007, as compared to $6,614,000 at
December 31, 2006.  The decrease was largely caused by the investment in
equipment and facility improvements related to an effort to gain compliance
with current Good Manufacturing Practices (cGMP) regulations in its
manufacturing operations.  Shareholders' equity increased by 3%, or
$310,000, to $9,642,000 at June 30, 2007, as compared to $9,332,000 at
December 31, 2006.  The Company had 2,906,000 shares of common stock
outstanding as of June 30, 2007.
</p>
<p>
<pre>
                                          (Unaudited)       (Unaudited)
                                       Three Months Ended  Six Months Ended
                                            June 30,          June 30,
                                        ----------------  -----------------
(In thousands, except per share
 amounts)                                 2007     2006     2007     2006
                                        -------  -------  -------- --------
Revenues:
Product sales                           $   791  $   749  $  2,300 $  2,187
Other revenues                              168       93       335      198
                                        -------  -------  -------- --------
Total revenues                              959      842     2,635    2,385

Cost and expenses:
Product costs                               511      386     1,141      895
Product development expenses                294      231       560      466
Selling, general and administrative
 expenses                                   307      257       656      599
                                        -------  -------  -------- --------
Total costs and expenses                  1,112      874     2,357    1,960
                                        -------  -------  -------- --------

Net operating (loss) income                (153)     (32)      278      425

Interest and other income                    70       64       146      116
                                        -------  -------  -------- --------

Income (loss) before income taxes           (83)      32       424      541
Income tax expense (credit)                 (23)      16       187      219
                                        -------  -------  -------- --------
Net income (loss)                       $   (60) $    16  $    237 $    322
                                        =======  =======  ======== ========

Net income (loss) per common share:
Basic                                   $ (0.02) $  0.01  $   0.08 $   0.11
Diluted                                 $ (0.02) $  0.01  $   0.08 $   0.11

Weighted average common shares
 outstanding:
Basic                                     2,903    2,893     2,900    2,872
Diluted                                   2,903    3,073     3,066    3,055




                                                                (Unaudited)
                                               At December 31,  At June 30,
(In thousands)                                      2006           2007
                                                ------------   ------------
Cash, cash equivalents and short-term
 investments                                    $      6,614   $      5,524
Total assets                                          11,364         10,847
Net working capital                                    6,934          5,815
Stockholders&#146; equity                            $      9,332   $      9,642
</pre>
</p>
<p>
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries.  Press releases and other
information about the Company are available at http://www.immucell.com.

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
